Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021
April 08 2021 - 7:30AM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a
clinical-stage pharmaceutical company developing novel, targeted
and personalized therapies for rare and difficult to treat cancers,
announced that the Company will report first quarter 2021 financial
results on Thursday, April 22, 2021, after market close. Plus
Therapeutics’ management team will then host a conference call and
webcast at 5:00 p.m. Eastern Time to discuss the financial results
and provide a corporate update.
A live webcast will be available at
ir.plustherapeutics.com/events
Please refer to the information below for conference call
dial-in information. Callers should dial in approximately 10
minutes prior to the start of the call.
Conference dial-in: |
877-402-3914 |
International dial-in: |
631-865-5294 |
Conference ID: |
3084418 |
Conference Call Name: |
Plus Therapeutics First Quarter
2021 Results Conference Call |
Following the live call, a replay will be available on the
Company’s website under the 'Investor Relations' section. The
webcast will be available on the Company’s website for 90 days
following the live call.
About Plus Therapeutics,
Inc.
Plus Therapeutics (Nasdaq: PSTV) is a
clinical-stage pharmaceutical company whose radiotherapeutic
portfolio is concentrated on nanoliposome-encapsulated
radionuclides for several cancer targets. Central to the Company’s
drug development is a unique nanotechnology platform designed to
reformulate, deliver and commercialize multiple drugs targeting
rare cancers and other diseases. The platform is designed to
facilitate new delivery approaches and/or formulations of safe and
effective, injectable drugs, potentially enhancing the safety,
efficacy and convenience for patients and healthcare providers.
More information may be found
at PlusTherapeutics.com and ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains certain statements
that may be deemed “forward-looking statements” within the meaning
of U.S. securities laws. All statements, other than statements of
historical fact, that address activities, events or developments
that we intend, expect, project, believe or anticipate and similar
expressions or future conditional verbs such as will, should,
would, could or may occur in the future are forward-looking
statements. Such statements are based upon certain assumptions and
assessments made by our management in light of their experience and
their perception of historical trends, current conditions, expected
future developments and other factors they believe to be
appropriate. These statements include, without limitation,
statements about: the Company’s potential to facilitate new
delivery approaches and/or formulations of safe and effective,
injectable drugs, potentially enhancing the safety, efficacy and
convenience for patients and healthcare providers; the Company’s
potential to develop drug candidates currently in its product
pipeline; and the Company’s potential to develop additional drugs
outside of its current pipeline. The forward-looking statements
included in this press release are subject to a number of
additional material risks and uncertainties, including but not
limited to: the risk that the Company is not able to successfully
develop product candidates that can leverage the U.S. FDA’s
accelerated regulatory pathways; and the risks described under the
heading “Risk Factors” in the Company’s Securities and Exchange
Commission filings, including in the Company’s annual and quarterly
reports. There may be events in the future that the Company is
unable to predict, or over which it has no control, and its
business, financial condition, results of operations and prospects
may change in the future. The Company assumes no responsibility to
update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made unless the
Company has an obligation under U.S. federal securities laws to do
so.
Investor ContactPeter VozzoWestwicke/ICR(443)
377-4767 Peter.Vozzo@westwicke.com
Media ContactTerri ClevengerWestwicke/ICR(203)
856-4326Terri.Clevenger@westwicke.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Apr 2023 to Apr 2024